glp 1 approved for nash GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives tirzepatide nash Beyond glycemia: Comparing

The success of GLP-1-based therapies in transforming obesity and diabetes treatment is nothing short of revolutionary

The clinical evidence base for tirzepatide as a GLP-1+GIP agonist is similarly strong, with trial data showing substantial weight reduction in studied populations

If youre suffering, check with your doctor If going on a GLP-1 suppresses your appetite to the point that youre not interested in eating at all, or if youre vomiting frequently or severely constipated, reach out to your provider: Your GLP-1 dosing may need to be lowered

doi: 10.1210/clinem/dgab103 50 TanMLamendolaCLuongRMcLaughlinTCraigC

Although GLP-1s arent officially approved for this use, some longevity-focused doctors are prescribing them off-label as part of a broader prevention plan due to all the potential benefits

510 % average body-weight loss